Literature DB >> 12626849

Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease.

Haruo Hanyu1, Takeshi Shimizu, Yuriko Tanaka, Masaru Takasaki, Kiyoshi Koizumi, Kimihiko Abe.   

Abstract

We attempted to identify the characteristic patterns in regional cerebral blood flow (rCBF) of patients with Alzheimer's disease who responded to donepezil therapy. Sixty-one patients treated with donepezil were divided into two groups (responders and nonresponders) on the basis of changes in their Mini Mental State Examination (MMSE) scores from baseline to study endpoint. We analyzed single-photon emission computed tomography data (SPECT) at baseline using three-dimensional stereotactic surface projections and compared differences in rCBF between the two groups. Statistical maps showed a significantly lower rCBF of the lateral and medial frontal lobes in the nonresponders than in the responders. There was a significant inverse correlation between the relative rCBF reduction in the frontal lobe and the MMSE change. These results suggest that frontal function, as assessed by SPECT, affects the patient's response to treatment with donepezil. Measuring rCBF may aid in the selection of possible treatment responders. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626849     DOI: 10.1159/000068785

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  15 in total

1.  Ultrasonographic measurement of cerebral blood flow, cerebral circulation time and cerebral blood volume in vascular and Alzheimer's dementia.

Authors:  Stephan J Schreiber; Florian Doepp; Eike Spruth; Ute A Kopp; José M Valdueza
Journal:  J Neurol       Date:  2005-09-12       Impact factor: 4.849

2.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- against.

Authors:  Alberto Pupi; Flavio Mariano Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

3.  The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque.

Authors:  Jason M Uslaner; Donnie Eddins; Vanita Puri; Christopher E Cannon; Jane Sutcliffe; Chan Sing Chew; Michelle Pearson; Jeffrey A Vivian; Ronald K Chang; William J Ray; Scott D Kuduk; Marion Wittmann
Journal:  Psychopharmacology (Berl)       Date:  2012-07-24       Impact factor: 4.530

4.  Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.

Authors:  E Stefanova; A Wall; O Almkvist; A Nilsson; A Forsberg; B Långström; A Nordberg
Journal:  J Neural Transm (Vienna)       Date:  2005-07-29       Impact factor: 3.575

5.  Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment.

Authors:  Wenjun Li; Piero G Antuono; Chunming Xie; Gang Chen; Jennifer L Jones; B Douglas Ward; Malgorzata B Franczak; Joseph S Goveas; Shi-Jiang Li
Journal:  Neuroimage       Date:  2012-01-08       Impact factor: 6.556

Review 6.  Toward the validation of functional neuroimaging as a potential biomarker for Alzheimer's disease: implications for drug development.

Authors:  Alberto Pupi; Lisa Mosconi; Flavio M Nobili; Sandro Sorbi
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

7.  Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review.

Authors:  Federico Emanuele Pozzi; Elisa Conti; Ildebrando Appollonio; Carlo Ferrarese; Lucio Tremolizzo
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

8.  Differences in regional cerebral blood flow patterns in male versus female patients with Alzheimer disease.

Authors:  Haruo Hanyu; Soichiro Shimizu; Yuriko Tanaka; Masaru Takasaki; Kiyoshi Koizumi; Kimihiko Abe
Journal:  AJNR Am J Neuroradiol       Date:  2004-08       Impact factor: 3.825

Review 9.  M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Shangtong Jiang; Yanfang Li; Cuilin Zhang; Yingjun Zhao; Guojun Bu; Huaxi Xu; Yun-Wu Zhang
Journal:  Neurosci Bull       Date:  2014-03-03       Impact factor: 5.203

Review 10.  The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).

Authors:  C C Gispen-de Wied; M Kritsidima; A J A Elferink
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.